Core Insights - Guangxi's pharmaceutical exports have shown significant growth, with a 27.23% year-on-year increase in the first three quarters, reaching 869 million yuan, following a 12.29% growth last year [1] - The region has optimized regulatory services and enhanced international competitiveness, leading to a rise in the number of pharmaceutical companies and products obtaining export certifications [1] - The recognition of the quality of "Made in Guangxi" pharmaceuticals in international markets has contributed to this growth [1] Group 1: Export Growth and Achievements - In the first three quarters, 22 pharmaceutical companies in Guangxi obtained 88 export sales certificates, marking increases of 37.5% and 66.04% respectively [1] - Eight companies received EU raw material drug export certifications for 21 products, with growth rates of 300% and 600% [1] - Guilin South Pharmaceutical Co. and Nanning Yinchuan Meishi Pharmaceutical Co. each surpassed 100 million yuan in annual exports, with Guilin South's anti-malarial drug revenue reaching 424 million yuan [1] Group 2: Product Diversification and Market Expansion - There is a trend towards high-end products, with traditional exports like anti-malarial and raw materials being complemented by traditional Chinese medicine and high-value products [2] - The number of traditional Chinese medicine export varieties increased by 35%, with products entering new markets such as Peru, Singapore, and Malaysia [2] - Guangxi has expanded cooperation with ASEAN countries through various initiatives, including hosting the China-ASEAN Pharmaceutical Cooperation Development Forum and establishing research bases [2]

Group 1 - The core stock price of Kangchen Pharmaceutical (01681.HK) reached 9.760 HKD, marking a 4.27% increase from the previous trading day, with an intraday high of 9.900 HKD, the highest in nearly a year [1] - The net capital inflow for the day was 12.65 million HKD, with a total inflow of 24.97 million HKD and outflow of 12.32 million HKD [1] - Kangchen Pharmaceutical Group Limited, founded in 1997 and listed in Hong Kong in 2013, operates under well-known brands such as Kangchen and Yulin, with business spanning over 30 countries and regions [1] Group 2 - The company has established four production bases in Guangdong Guangzhou, Inner Mongolia Tongliao, Guangxi Yulin, and Xinjiang Horgos, employing over 3,000 people [2] - Kangchen Pharmaceutical focuses on nephrology as its flagship area, with a diverse product portfolio of 138 varieties, including 62 traditional Chinese medicine and 76 Western medicine products, with 33 varieties listed in the national essential drug list and 67 in the national medical insurance catalog [2] - The company has invested in a "Kidney Disease Drug Research Center" and collaborates with prestigious universities for research and development, aiming to become a leading pharmaceutical enterprise across multiple specialties [2]